People

Brett J. Bromann

Senior Associate

Bromann_Brett_lo

Brett Bromann has a general corporate practice, with a focus on capital markets transactions and emerging companies.

Mr. Bromann was previously a summer associate at WilmerHale. While in law school, he was involved with the University of Chicago Law School’s Corporate Lab, where he worked on corporate, regulatory and tax matters for multinational companies. He also served as an intern in the Office of the Prosecutor at the United Nations International Criminal Tribunal for Rwanda in Arusha, Tanzania, where he worked in the appellate division in the ongoing prosecution of those responsible for the 1994 Rwandan genocide.

Publications & News

View

May 8, 2018

WilmerHale Counsels Karyopharm Therapeutics in Public Offering of Shares

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, has announced the closing of its previously announced registered underwritten public offering and the exercise in full of the underwriters' option to purchase additional shares.

April 11, 2018

WilmerHale Counsels Analogic in $1.1B Acquisition by an Affiliate of Altaris Capital Partners

On April 10, 2018, Analogic Corporation, a provider of leading-edge healthcare and security solutions, and Altaris Capital Partners, LLC, a leading private investment firm with expertise in Analogic's end markets, announced that they have entered into a merger agreement under which Analogic will be acquired by Altaris for approximately $1.1 billion on a fully diluted basis.

February 28, 2018

WilmerHale Represents Generation Bio in $100M Series B Financing

Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, recently announced the closing of a $100 million Series B financing.

November 29, 2017

WilmerHale Reps Voyager Therapeutics in Public Offering of Common Stock

Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, announced the closing of its underwritten public offering of 5,175,000 shares of its common stock.

November 6, 2017

WilmerHale Represents 1366 Technologies in $9M Series D Funding

Developer of manufacturing solutions for silicon cell manufacturers, 1366 Technologies, has raised $9 million in Series D funding from strategic partners and return investors.

October 5, 2017

WilmerHale Reps Disarm Therapeutics in $30M Series A Financing

Disarm Therapeutics, a new biotechnology company developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration, announced the recent completion of a $30 million Series A financing.

July 11, 2017

Staples, Inc. Enters Into Definitive Agreement to Be Acquired by Sycamore Partners for $10.25 per Share in Cash, or Approximately $6.9 Billion

Staples, Inc. and Sycamore Partners, a leading private equity firm, announced that they have entered into a merger agreement in which investment funds managed by Sycamore Partners will acquire Staples in a transaction that values Staples at an equity value of approximately $6.9 billion.

December 23, 2016

WilmerHale Reps Editas Medicine in Licensing of New Technologies

Editas Medicine, Inc., a leading genome editing company, announced it has exclusively licensed intellectual property related to new CRISPR technologies for human therapeutics that will enhance and broaden the range of medicines the company can develop.

September 22, 2016

WilmerHale Advises Agios Pharmaceuticals in $173M Public Offering and Full Exercise of Option to Purchase Additional Shares

The WilmerHale team was led by Partner Steven Singer and included Special Counsel Cynthia Mazareas, Senior Associate Mhairi Immermann and Associate Brett Bromann.

February 3, 2016

WilmerHale Reps Editas Medicine in $94.4 Million IPO

WilmerHale represented Massachusetts-based gene editing company Editas Medicine in its $94.4 million initial public offering, which occurred on February 2, 2016.

Practices

Skip Navigation Links.

Education

JD, University of Chicago Law School, 2014, Business Editor, University of Chicago Legal Forum

BA, Psychology, magna cum laude, Boston College, 2011

Bar Admissions

Massachusetts

Skip Navigation Links.